Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0U0XL
|
|||
| Former ID |
DIB009051
|
|||
| Drug Name |
NN-7415
|
|||
| Synonyms |
NNC-0172-0000-2021
Click to Show/Hide
|
|||
| Indication | Factor IX deficiency [ICD-11: 3B11; ICD-10: D67] | Phase 1 | [1] | |
| Company |
Novo Nordisk A/S
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tissue factor pathway inhibitor (TFPI) | Target Info | Modulator | [2] |
| KEGG Pathway | Complement and coagulation cascades | |||
| NetPath Pathway | IL4 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| Panther Pathway | Blood coagulation | |||
| Pathway Interaction Database | Syndecan-4-mediated signaling events | |||
| Reactome | Extrinsic Pathway of Fibrin Clot Formation | |||
| WikiPathways | Complement and Coagulation Cascades | |||
| Integrated Breast Cancer Pathway | ||||
| Formation of Fibrin Clot (Clotting Cascade) | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01228669) Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B. U.S. National Institutes of Health. | |||
| REF 2 | Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial.J Thromb Haemost.2015 May;13(5):743-54. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.